MannKind Corporation (MNKD)

NASDAQ • Healthcare

$3.19

-$0.01 (-0.3%)

Market open

Last close at October 23, 2026 at 20:00 UTC

Open$3.18

Previous Close$3.19

Day Range$3.09 - $3.21

Avg. Volume (3M)4.5M

Market Cap$1B

52 Week Range

$2.23$6.51

Next EarningsIn 10 daysNov 4, 2026

Metrics Over Time

Where the Money Goes

Q2 2026

Revenueeverything earned$109.3M100%

Gross Profitminus cost of goods$79.8M73%

In plain terms: out of every $100 in revenue, MannKind Corporation currently loses $17.

Fundamentals & Financials

Revenue (TTM)

$393.6M

Net Income (TTM)

-$43.6M

EPS (TTM)

-$0.14

ROA (TTM)

-5.96%

Current Ratio

1.72

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Income Statement

Balance Sheet

Financial Highlights

Dividends History

Split History

Earnings

-94.6%Q3 2025$0

+200.0%Q4 2025$0.03

-400.0%Q1 2026-$0.05

-150.0%Q2 2026-$0.05

-700.0%Q3 2026-$0.06

Nov 4

in 10 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Next report — what to expect

MannKind Corporation (MNKD) reports on November 4, 2026. Wall Street expects EPS of -$0.08 on revenue of $110.3 million. For trailing context, revenue grew +42.9% year over year last quarter. MannKind has beaten EPS in 2 of its 8 most recent quarters, so focus on update drivers versus consensus.

View full earnings history

About MannKind Corporation

MannKind Corporation develops and commercializes respiratory-delivered therapies in biotechnology and trades on the NASDAQ under MNKD. Its work centers on endocrine and pulmonary drug products, led by Afrezza and Thyquidity, and it generated $349.0 million of revenue in FY2025 from marketed therapies and development-stage programs.

Name

MannKind Corporation

CEO

Michael E. Castagna

Website

www.mannkindcorp.com

Industry

Healthcare

Year Founded

1991

Employees

592

Today's Snapshot

AI-generated

MNKD closed slightly lower at 3.19, while its sector was weaker. Earnings are due from MNKD on 4 November.

Trading Volume

Below 10d avg (3.6M)

2.6M

vs S&P 500 Today

Moderate Outperformance

+0.21%

Updated: October 23, 2026 at 20:12 UTC

MNKD Headlines

FDA clears Afrezza pediatric use

May 29, 2026

3 min read

View All News

Technical Indicators

1 Buy3 Neutral4 Sell

MNKD presents a mixed but overall bearish setup: the current price near 3.19 sits around short-term averages that show slight support while medium- and long-term averages remain higher, signaling a longer-term downtrend. Momentum readings are weak and MACD is neutral-to-negative, ADX indicates a lack of strong directional trend, and OBV points to persistent selling pressure. Volatility is moderate with ATR near 6% of price, and the pivot level is close to the market. Technical takeaway: short-term support contrasts with broader moving-average resistance and selling volume, aligning with a sell bias.

All signals

EMA (5 indicators)$3.18 - $4.01
Sell
RSI (14)42.72
Neutral
Stochastic %K (14, 3, 3)24.99
Neutral
MACD Level (12, 26)-0.16
Neutral

Peers & Related Assets

XERSXeris Biopharma Holdings, Inc.

$10.2-6.1%

TBPHTheravance Biopharma Inc

$17.030.0%

SPRYARS Pharmaceuticals, Inc.

$4.03-6.7%

AVLNAvalyn Pharma Inc. Common Stock

ORMPOramed Pharmaceuticals Inc.

NRXPNRx Pharmaceuticals, Inc.

Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.